Categoria Articoli Scientifici
Final Results From the Randomized Phase III ASCENT...
Pembrolizumab or placebo with chemoradiotherapy...
Translational and therapeutic evaluation of RAS-GTP...
Ribociclib plus Endocrine Therapy in Early Breast...
Enfortumab Vedotin and Pembrolizumab in Untreated...
Final analysis of phase II results with cemiplimab in...
Four-year overall survival update from the phase III...
International Pooled Analysis of Leisure-Time Physical...
Joint report SIPMO-SIOMMMS sulla MRONJ in pazienti in...
Osimertinib with or without Chemotherapy in EGFR...
Fluorouracil, Leucovorin, and Irinotecan Plus...
Toripalimab plus nab-paclitaxel in metastatic or...
Pregnancy After Breast Cancer in Young BRCA Carriers:...
Nivolumab plus Gemcitabine–Cisplatin in Advanced...
Tarlatamab for Patients with Previously Treated Small...
Biomarker Data from the Phase III KATHERINE Study of...
NALIRIFOX versus nab-paclitaxel and gemcitabine in...
Three-Year Overall Survival with Tebentafusp in...
Randomized Trial of Exercise and Nutrition on...
A Phase 3, Randomized study of atezolizumab plus...
Sotorasib plus Panitumumab in Refractory Colorectal...
Trends and Characteristics of Potentially Preventable...
Opioid-induced Neurotoxicity in Patients with Cancer...
Fruquintinib versus placebo in patients with...
Association Between Duration of Immunotherapy and...
Risk of Further Progression or Death Among Durable...
Initial Panitumumab Plus Fluorouracil, Leucovorin, and...
Is Acetaminophen Beneficial in Patients With Cancer...
Perioperative Nivolumab and Chemotherapy in Stage III...
Trastuzumab deruxtecan in patients in the USA and...
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Atezolizumab plus cabozantinib versus cabozantinib...
Temporary treatment cessation versus continuation of...
Trifluridine–Tipiracil and Bevacizumab in Refractory...
Panitumumab vs Bevacizumab Added to Standard First...
Pembrolizumab plus Chemotherapy in Advanced...
Targeting neuroendocrine tumors with octreotide and...
Dostarlimab for Primary Advanced or Recurrent...
Fifteen-Year Outcomes after Monitoring, Surgery, or...
An international, open-label, randomised trial...
Lobar or Sublobar Resection for Peripheral Stage IA...
Rucaparib or Physician’s Choice in Metastatic Prostate...
Adjuvant Osimertinib for Resected EGFR-Mutated Stage...
Cancer in Transgender and Gender-Diverse Persons: A...
Futibatinib for FGFR2-Rearranged Intrahepatic...
Olaparib Efficacy in Patients with Metastatic...
Overall Survival With Maintenance Olaparib at a 7-Year...
Adagrasib with or without Cetuximab in Colorectal...
Pembrolizumab Versus Placebo as Second-Line Therapy in...
Overall survival with first-line atezolizumab in...
Upfront FOLFOXIRI plus bevacizumab with or without...
Effect of Colonoscopy Screening on Risks of Colorectal...
First-line avelumab for patients with PD-L1-positive...
Five-Year Survival Outcomes With Nivolumab Plus...
The Time Toxicity of Cancer Treatment
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous...
Addition of androgen receptor targeted agents to...
Pembrolizumab versus placebo as adjuvant therapy for...
Association of Upfront Peptide Receptor Radionuclide...
Circulating tumor DNA to guide rechallenge with...
Long-Term Outcomes and Genetic Predictors of Response...
Pembrolizumab plus Chemotherapy in Advanced Triple...
Modification of the Association Between Frequent...
Trastuzumab Deruxtecan in Previously Treated HER2-Low...
Nivolumab plus cabozantinib versus sunitinib in first...
Upfront Modified Fluorouracil, Leucovorin...
Adebrelimab or placebo plus carboplatin and etoposide...
Final Analysis of 3 Versus 6 Months of Adjuvant...
Temozolomide Followed by Combination With Low-Dose...
Neoadjuvant Nivolumab plus Chemotherapy in Resectable...
Androgen deprivation therapy use and duration with...
Trastuzumab Deruxtecan versus Trastuzumab Emtansine...
Nivolumab plus chemotherapy or ipilimumab in gastro...
Darolutamide and Survival in Metastatic, Hormone...
Aromatase inhibitors versus tamoxifen in premenopausal...
Event-free Survival with Pembrolizumab in Early Triple...
Final Overall Survival and Molecular Analysis in...
Survival with Cemiplimab in Recurrent Cervical Cancer
Systemic therapies for preventing or treating...
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery...
Nivolumab Combination Therapy in Advanced Esophageal...
Cabozantinib for radioiodine-refractory differentiated...
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade...
Belzutifan for Renal Cell Carcinoma in von Hippel...
Adjuvant Palbociclib for Early Breast Cancer: The...
Maintenance olaparib for patients with newly diagnosed...
Lutetium-177-PSMA-617 for Metastatic Castration...
Genomic Profiling of Lung Adenocarcinoma in Never...
Uptake and Survival Outcomes Following Immune...
Quality of Life in Men With Prostate Cancer Randomly...
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus...
Extended therapy with letrozole as adjuvant treatment...
Pembrolizumab for Persistent, Recurrent, or Metastatic...
Cetuximab Rechallenge Plus Avelumab in Pretreated...
Benefits and Harms of Lung Cancer Screening by Chest...
Adjuvant atezolizumab after adjuvant chemotherapy in...
Gemcitabine with or without ramucirumab as second-line...
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell...
